Stem Cell and Regenerative Medicine Section, University College London GOS Institute of Child Health, London, UK.
Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, Shanghai, China.
Nat Commun. 2019 Dec 11;10(1):5658. doi: 10.1038/s41467-019-13605-4.
Organoids have extensive therapeutic potential and are increasingly opening up new avenues within regenerative medicine. However, their clinical application is greatly limited by the lack of effective GMP-compliant systems for organoid expansion in culture. Here, we envisage that the use of extracellular matrix (ECM) hydrogels derived from decellularized tissues (DT) can provide an environment capable of directing cell growth. These gels possess the biochemical signature of tissue-specific ECM and have the potential for clinical translation. Gels from decellularized porcine small intestine (SI) mucosa/submucosa enable formation and growth of endoderm-derived human organoids, such as gastric, hepatic, pancreatic, and SI. ECM gels can be used as a tool for direct human organoid derivation, for cell growth with a stable transcriptomic signature, and for in vivo organoid delivery. The development of these ECM-derived hydrogels opens up the potential for human organoids to be used clinically.
类器官具有广泛的治疗潜力，在再生医学领域不断开辟新途径。然而，由于缺乏有效的符合 GMP 标准的类器官培养扩增系统，其临床应用受到极大限制。在这里，我们设想使用源自脱细胞组织 (DT) 的细胞外基质 (ECM) 水凝胶可以提供一个能够指导细胞生长的环境。这些凝胶具有组织特异性 ECM 的生化特征，具有临床转化的潜力。源自脱细胞猪小肠 (SI) 黏膜/黏膜下层的凝胶可促进内胚层来源的人类类器官的形成和生长，如胃、肝、胰腺和 SI 类器官。ECM 凝胶可用作直接衍生人类类器官的工具，用于具有稳定转录组特征的细胞生长，以及用于体内类器官递送。这些 ECM 衍生水凝胶的开发为临床应用人类类器官开辟了潜力。
